Sun Pharmaceutical Industries Limited, commonly known as Sun Pharma, has been at the forefront of advancing patient care in dermatology, particularly in the treatment of conditions such as psoriasis, alopecia areata, and acne. At the recent 2026 AAD Annual Meeting held in Denver, Colorado, the company presented a total of 14 abstracts, showcasing its ongoing commitment to innovation in these therapeutic areas.
Among the key highlights was ILUMYA, which is focused on treating moderate-to-severe plaque psoriasis and nail psoriasis. This drug has been pivotal in improving the quality of life for many patients suffering from these challenging skin conditions. Additionally, LEQSELVI, designed for severe alopecia areata treatment, has garnered attention for its potential to change the treatment landscape for this often debilitating condition.
WINLEVI, another significant product, is indicated for acne vulgaris and is part of combination therapies aimed at providing comprehensive care for patients dealing with acne. These advancements reflect Sun Pharma’s dedication to addressing the diverse needs of dermatology patients.
However, not all news was positive. The Phase II FLASH study for Fibromun did not meet its primary endpoint for progression-free survival (PFS), raising questions about the future of this treatment. In contrast, Nidlegy showed promising results, achieving complete pathological responses in 52.6% of patients in the Phase II ‘Duncan’ study, indicating its potential effectiveness.
Furthermore, the GLIOSTELLA study, which focuses on late-line glioblastoma, has completed enrollment in the U.S., marking a significant step forward in cancer treatment research. Following the withdrawal of a prior Marketing Authorization Application in 2025, a new submission for Nidlegy is currently being prepared, reflecting Sun Pharma’s resilience and commitment to bringing effective therapies to market.
Dr. Ahmad Naim, a representative from Sun Pharma, emphasized the importance of their findings, stating, “The data we are presenting at AAD underscore our commitment to advancing dermatology and immunology through meaningful science – spanning not only clinical efficacy and safety, but also how these therapies perform over time and in real-world practice.” This statement encapsulates the company’s vision for the future of dermatological treatments.
As the industry watches closely, observers expect Sun Pharma to continue its trajectory of innovation and research, potentially reshaping the landscape of dermatological care. The outcomes of these studies and the subsequent regulatory submissions will be critical in determining the next steps for the company and its product offerings.
